Inferra AIResearch Tools

Inferra AI / Company / A

Agilent Technologies

A · Health Care

Last earnings Aug 26, 2026

Key results

GAAP net incomequarter

$336 million

GAAP net income of $336 million earnings per share (EPS) of $1.18, up 22% from the third quarter of 2024.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

EPSquarter

$1.18

GAAP net income of $336 million earnings per share (EPS) of $1.18, up 22% from the third quarter of 2024.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Growthquarter

up 22%

GAAP net income of $336 million earnings per share (EPS) of $1.18, up 22% from the third quarter of 2024.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Net incomequarter

$390 million

Non-GAAP (2) net income of $390 million EPS of $1.37, up 4% from the third quarter of 2024.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Third-quarter GAAP net incomequarter

$336 million

Third-quarter GAAP net income was $336 million, or $1.18 per share.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Non-GAAP (2) net income was $390 million, or $1.37 per share during the quarter, compared with $385 million or $1.32 per share during the year-ago quarter.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Revenuequarter

$670 million

Life Sciences and Diagnostics Markets Group The Life Sciences and Diagnostics Markets Group (LDG) reported third-quarter revenue of $670 million, an increase of 14% reported and 7% core (1) year-over-year.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Operating marginquarter

17.6%

LDG s operating margin for the quarter was 17.6%.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Agilent CrossLab Group The Agilent CrossLab Group (ACG) reported third-quarter revenue of $744 million, an increase of 8% reported and 5% core (1) year-over-year.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

ACG s operating margin for the quarter was 33.3%.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

AI analysis

Q3 FY2025 · reported Aug 27, 2025

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Revenue · Q3 FY2025
$670M
EX-99 · Aug 27, 2025
EPS · Q3 FY2025
$1.18
EX-99 · Aug 27, 2025
GAAP net income · Q3 FY2025
$336M
EX-99 · Aug 27, 2025
Net income · Q3 FY2025
$390M
EX-99 · Aug 27, 2025

The quarter in charts

Guidance ladder — revenue

Delivered vs the company's guided range

EX-99 · Aug 27, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.

Headline figures

MetricQ3 FY2025Prior qtrYear ago
GAAP net income$336 million——
EPS$1.18——
Growthup 22%——
Net income$390 million——
Third-quarter GAAP net income$336 million——
Revenue$670 million——
Operating margin17.6%——

EX-99 · Aug 27, 2025

Guidance · company-stated

Direction: Raised

Revenue$1.74 billion

“htm EX-99.1 Document Exhibit 99.1 Agilent Reports Third-Quarter Fiscal Year 2025 Financial Results Agilent delivers strong revenue growth, raises growth outlook Highlights Revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% on a core (1) basis compared with the third quarter of 2024.”

Revenue

“Q4 revenue outlook is expected to be in the range of $1.822 billion to $1.842 billion, an increase of 7.1% to 8.3% reported and up 4.8% to 6.0% core (1) .”

Midpoint vs latest-quarter revenue+159.7%computed from stated figures

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Margin

Operating margin17.6%

Capital allocation

The estimated fair value of restricted stock units and LTPP-EPS awards is determined based on the market price of our common stock on the date of grant adjusted for expected dividend yield.

The model used the same historical stock price volatility and dividend yield assumption used for the Monte Carlo simulation model and an expected dividend yield to compute the discount.

What changed vs last quarter

  • Guide midpoint vs latest-quarter revenue +159.7% computed from stated figures
General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

GAAP net income of $336 million earnings per share (EPS) of $1.18, up 22% from the third quarter of 2024

Based on: Earnings release + parent 8-K + 10-Q — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “htm EX-99.1 Document Exhibit 99.1 Agilent Reports Third-Quarter Fiscal Year 2025 Financial Results Agilent delivers strong revenue growth, raises growth outlook Highlights Revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% on a core (1) basis compared with the third quarter of 2024.”

Revenue: “Q4 revenue outlook is expected to be in the range of $1.822 billion to $1.842 billion, an increase of 7.1% to 8.3% reported and up 4.8% to 6.0% core (1) .”

Revenue — Raised (“raises”)
“htm EX-99.1 Document Exhibit 99.1 Agilent Reports Third-Quarter Fiscal Year 2025 Financial Results Agilent delivers strong revenue growth, raises growth outlook Highlights Revenue of $1.74 billion for the third quarter ended July 31, 2025, exceeding revenue guidance and representing growth of 10.1% reported and up 6.1% on a core (1) basis compared with the third quarter of 2024.”

Revenue — Raised (“increase”)
“Q4 revenue outlook is expected to be in the range of $1.822 billion to $1.842 billion, an increase of 7.1% to 8.3% reported and up 4.8% to 6.0% core (1) .”

Classified from the release's primary full-year outlook statement.

Capital allocation

The estimated fair value of restricted stock units and LTPP-EPS awards is determined based on the market price of our common stock on the date of grant adjusted for expected dividend yield.

SEC original ↗Agilent Technologies — 10-Q Quarterly report10-QSep 1, 2026

The model used the same historical stock price volatility and dividend yield assumption used for the Monte Carlo simulation model and an expected dividend yield to compute the discount.

SEC original ↗Agilent Technologies — 10-Q Quarterly report10-QSep 1, 2026

Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares.

SEC original ↗Agilent Technologies — 10-Q Quarterly report10-QSep 1, 2026

Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities.

SEC original ↗Agilent Technologies — 10-Q Quarterly report10-QSep 1, 2026

Strategy & priorities

Our third-quarter performance, which marks our fifth consecutive quarter of sequential core-revenue acceleration, is a testament to the success of our Ignite Transformation and our laser-like 1 focus on profitable growth and operational excellence, said Agilent President and CEO Padraig McDonnell.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Our Ignite enterprise operating model enables us to nimbly and quickly navigate a highly dynamic macro environment while remaining focused on our strong execution, innovation pipeline, and deep customer relationships.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

The forward-looking statements contained herein include, but are not limited to, information regarding Agilent s growth prospects, business, financial results, revenue, non-GAAP earnings guidance for Q4 and fiscal year 2025, and the effects of its new organizational structure, operational transformation and market-focused strategy.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

(2) Non-GAAP net income and non-GAAP earnings per share primarily exclude the impacts of restructuring and other related costs, intangibles amortization, transformational initiatives, acquisition and integration costs and net (gain) loss on equity securities.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

(3) Non-GAAP earnings per share as projected for Q4 fiscal year 2025 and full fiscal year 2025 exclude primarily the estimated impacts of non-cash intangibles amortization, transformational initiatives, and acquisition and integration costs.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Risks & headwinds

These results reflect a full quarter of the dynamic tariff environment.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

These forward-looking statements involve risks and uncertainties that could cause Agilent s results to differ materially from management s current expectations.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Such risks and uncertainties include, but are not limited to, unforeseen changes in the strength of Agilent s customers businesses unforeseen changes in the demand for current and new products, technologies, and services unforeseen changes in the currency markets customer purchasing decisions and timing and the risk that Agilent is not able to realize the savings expected from integration and restructuring activities.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Other includes certain legal costs and settlements, consulting costs, special compliance costs, acceleration of stock-based compensation expense, impact of the difference between current and inflated tariff rates between USA and China for the first two weeks of May 2025 and other miscellaneous adjustments.

SEC original ↗Agilent Technologies — Earnings release (8-K exhibit)EX-99Aug 27, 2025

Legal Proceedings 55 Item 1A.

SEC original ↗Agilent Technologies — 10-Q Quarterly report10-QSep 1, 2026

See Part II, Item 1A, "Risk Factors" for additional discussion of such risks and uncertainties.

SEC original ↗Agilent Technologies — 10-Q Quarterly report10-QSep 1, 2026

Competitors

Competitors & peers

Named in the company’s own filings

Danaher Corporation (DHR)“Our principal competitors in the Life Sciences and Diagnostics Markets arena include: AB Sciex., a division of Danaher Corporation, Avecia, a division of Nitto Denko, Bruker, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Roche Ventana Medical Systems, Inc., a member of the Roche Group, Shimadzu Corporation, Thermo Fisher Scientific Inc., Twist Bioscience Corporation and Waters C”Bruker Corp (BRKR)“Our principal competitors in the Life Sciences and Diagnostics Markets arena include: AB Sciex., a division of Danaher Corporation, Avecia, a division of Nitto Denko, Bruker, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Roche Ventana Medical Systems, Inc., a member of the Roche Group, Shimadzu Corporation, Thermo Fisher Scientific Inc., Twist Bioscience Corporation and Waters C”Thermo Fisher Scientific (TMO)“Our principal competitors in the Life Sciences and Diagnostics Markets arena include: AB Sciex., a division of Danaher Corporation, Avecia, a division of Nitto Denko, Bruker, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Roche Ventana Medical Systems, Inc., a member of the Roche Group, Shimadzu Corporation, Thermo Fisher Scientific Inc., Twist Bioscience Corporation and Waters C”Twist Bioscience Corp (TWST)“Our principal competitors in the Life Sciences and Diagnostics Markets arena include: AB Sciex., a division of Danaher Corporation, Avecia, a division of Nitto Denko, Bruker, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Roche Ventana Medical Systems, Inc., a member of the Roche Group, Shimadzu Corporation, Thermo Fisher Scientific Inc., Twist Bioscience Corporation and Waters C”Waters Corporation (WAT)“Our principal competitors in the Life Sciences and Diagnostics Markets arena include: AB Sciex., a division of Danaher Corporation, Avecia, a division of Nitto Denko, Bruker, Inc., Leica Biosystems, Inc., a division of Danaher Corporation, Roche Ventana Medical Systems, Inc., a member of the Roche Group, Shimadzu Corporation, Thermo Fisher Scientific Inc., Twist Bioscience Corporation and Waters C”
Documents

Filings

69 documents

Earnings releases

20 documents

Presentations

0 documents

No presentations for Agilent Technologies are held in this edition of the library.

Transcripts

0 documents

No transcripts for Agilent Technologies are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Agilent Technologies by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.